The Journal of Alzheimer’s Disease has published today the results of the first clinical trial of a Tau Aggregation Inhibitor (TAI) in Alzheimer’s disease (AD). This Phase II clinical trial, conducted by TauRx Therapeutics Ltd (a Singapore incorporated spinout from the University of Aberdeen), provided the basis and rationale for subsequent Phase III clinical trials of a TAI in AD currently in progress.
TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX™ in Alzheimer’s Disease
TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer’s disease into the second of its two Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s disease.
TauRx Therapeutics Achieves Enrolment Target in the First of its Two Phase III Clinical Trials of LMTX™ in Alzheimer’s Disease
TauRx Therapeutics Ltd today announced it has achieved its target enrolment of 833 subjects into one of its two ongoing multi-centre Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s Disease [AD].
Prof. Wischik, Chairman of TauRx Therapeutics, will present a scientific update at the 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy on the company’s global Phase 3 clinical trials; its tau aggregation inhibitor, LMTX™, is aimed at halting the progression of Alzheimer’s
TauRx Chairman and London-based principal investigator will highlight how access to investigational treatments for Alzheimer’s is changing the care model for people with cognitive impairment – now and in the future
Erste deutsche Patienten melden sich zu den klinischen Phase-3-Studien von LMTX™ zur Alzheimer-Krankheit an
Klinische Studien beginnen in Deutschland mit einem Tau-Aggregationshemmer (TAI) der zweiten Generation mit dem Ziel, das Fortschreiten von Alzheimer zu stoppen
Clinical trials get under way in Germany with a second-generation tau aggregation inhibitor (TAI) aimed at halting the progression of Alzheimer’s
Clinical research centers added to allow more patients to access a tau-based investigational treatment for mild to moderate Alzheimer’s disease
Chairman of TauRx and Dr Emer MacSweeney of Re:Cognition Health to speak at ADI Middle East Conference in Dubai on 8-9 December
Two innovative UK thought leaders in Alzheimer’s disease will be speaking at the upcoming 2nd Middle East and North Africa Conference of Alzheimer's Disease International this weekend.
In Croatia, three international leaders in Alzheimer’s discuss ongoing clinical trials and global dementia policy ahead of the G8 Dementia Research Summit in London next week
Professor Claude Wischik, Chairman of TauRx Therapeutics, Marc Wortmann, Executive Director of Alzheimer’s Disease International (ADI), and Prof. Ninoslav Mimica, President of Alzheimer Croatia, provide the latest news about ADI’s global dementia policy and the Croatian launch of a global Alzheimer’s Research Study